CE mark for AI prostate biopsy solution

AI-focused cancer diagnostics specialist Ibex Medical Analysis has revealed that its Galen Prostate tool has received CE mark certification under the In Vitro Diagnostic Medical Devices Regulation (IVDR). Galen Prostate is designed to support pathologists in primary diagnosis of prostate biopsies.

The device uses AI to analyse prostate biopsies prior to pathologists’ review, with the results providing diagnostic insights to help guide pathologists in their diagnosis. It incorporates algorithms trained using datasets from several worldwide pathology institutes.

As well as helping pathologists to diagnose cancer, Galen Prostate can provide additional insights, including tumor size, a Gleason score and associated morphologies for each cancer slide. It also offers decision support tools, which can help to speed up diagnostic turnaround while reducing subjectivity.

The device was awarded a CE mark under IVDR, the EU’s new regulatory standard, following a review which demonstrated its quality, development process, performance and safety.

Ibex Medical Analytics Head of Regulatory Affairs and Quality Assurance Dr. Yael Liebes-Peer commented: “Ibex continues to maintain the highest possible standards for its products, bringing cutting-edge computational solutions to improve outcomes of cancer care. Dedicated to our mission of providing every patient with an accurate, timely and personalised cancer diagnosis, we are proud to provide the market's first IVDR-certified product, elevating the quality of diagnosis for patients, pathologists, and laboratories.”

Get In Touch

If you have any questions for our medical sales recruitment agency team please call us on 01424 777745 or drop us an email at info@kirkhamyoung.co.uk – we're very happy to help.

Contact Us